Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy

References

• Nepovimova E, Janockova J, Misik J, et al. Orexin supplementation in narcolepsy treatment: a review. Med Res Rev. 2018;39(3):961–965.
   PubMed Web of Science ®Google Scholar
• Silber MH, Krahn LE, Olson EJ, et al. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197–202.
   PubMed Web of Science ®Google Scholar
• Ruoff C, Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Curr Med Res Opin. 2016;32(10):1611–1612.
   PubMed Web of Science ®Google Scholar
• Mahoney CE, Cogswell A, Koralnik IJ, et al. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83.
   PubMed Web of Science ®Google Scholar
• Levy S, McArthur I, Crow B, et al. Factors influencing time to diagnosis in childhood narcolepsy type 1. J Child Neurol. 2019 Mar 27. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Dodel R, Peter H, Spottke A, et al. Health-related quality of life in patients with narcolepsy. Sleep Med. 2007;8(7–8):733–741.
   PubMed Web of Science ®Google Scholar
• Philip P, Sagaspe P, Lagarde E, et al. Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Med. 2010;11(10):973–979.
   PubMed Web of Science ®Google Scholar
• Black J, Reaven NL, Funk S, et al. The Burden of Narcolepsy Disease (BOND) study: healthcare utilization and cost findings. Sleep Med. 2014;15(5):522–529.
   PubMed Web of Science ®Google Scholar
• Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13(3):419–425.
   PubMed Web of Science ®Google Scholar
• Szakács A, Chaplin JE, Tideman P, et al. A population-based and case-controlled study of children and adolescents with narcolepsy: health-related quality of life, adaptive behavior and parental stress. Eur J Paediatr Neurol. 2019;23(2):288–295.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57(11):2029–2033.
   PubMed Web of Science ®Google Scholar
• Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51.
   PubMed Web of Science ®Google Scholar
• de Biase S, Nilo A, Gigli GL, et al. Investigational therapies for the treatment of narcolepsy. Expert Opin Investig Drugs. 2017;26(8):953–963.
   PubMed Web of Science ®Google Scholar
• Keam S, Walker MC. Therapies for narcolepsy with or without cataplexy: evidence-based review. Curr Opin Neurol. 2007;20(6):699–703.
   PubMed Web of Science ®Google Scholar
• Jin L, Shi L, Zhang Y, et al. Antidepressants for the treatment of narcolepsy: a prospective study of 148 patients in northern China. J Clin Neurosci. 2019;63:27–31.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. SUNOSI (solriamfetol) tablets, for oral use. [Cited 2019 Apr 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
   Google Scholar
• Reading P. Cataplexy. Pract Neurol. 2019;19(1):21–27.
   PubMedGoogle Scholar
• Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, et al. An overview of the clinical uses, pharmacology, and safety of modafinil. ACS Chem Neurosci. 2018;9(2):151–158.
   PubMed Web of Science ®Google Scholar
• Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(4):554–556.
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in narcolepsy multicenter study group. Neurology. 2000 14;54(5):1166–1175.
   PubMed Web of Science ®Google Scholar
• Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 2000;1(2):109–116.
   PubMed Web of Science ®Google Scholar
• Roth T, Schwartz JR, Hirshkowitz M, et al. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med. 2007;3(6):595–602.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, D’Andrea DM, et al. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. Clin Ther. 2010;32(12):2074–2087.
   PubMed Web of Science ®Google Scholar
• Schwartz JR, Roth T, Drake C. Armodafinil in the treatment of sleep/wake disorders. Neuropsychiatr Dis Treat. 2010;6:417.
   PubMed Web of Science ®Google Scholar
• Black JE, Hull SG, Tiller J, et al. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. J Clin Sleep Med. 2010;6(5):458–466.
   PubMed Web of Science ®Google Scholar
• Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654–2662.
   PubMed Web of Science ®Google Scholar
• Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39.
   PubMed Web of Science ®Google Scholar
• Wise MS, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1712–1727.
   PubMed Web of Science ®Google Scholar
• Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739–752.
   PubMed Web of Science ®Google Scholar
• Black J, Swick T, Bogan R, et al. Impact of sodium oxybate,modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016;24:57–62.
   PubMed Web of Science ®Google Scholar
• Vienne J, Bettler B, Franken P, et al. Differential effects of GABAB receptor subtypes, gamma-hydroxybutyric acid, and baclofen on EEG activity and sleep regulation. J Neurosci. 2010;30(42):14194–14204.
   PubMed Web of Science ®Google Scholar
• Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6(5):415–421.
   PubMed Web of Science ®Google Scholar
• Huyts B, Brabant C, Tirelli E. Pitolisant and intravenous cocaine self-administration in mice. Eur J Pharmacol. 2019;851:63–68.
   PubMed Web of Science ®Google Scholar
• Irukayama-Tomobe Y, Yanagisawa M. Development of a therapeutic drug for narcolepsy. Brain Nerve. 2018;70(11):1255–1263.
   PubMedGoogle Scholar
• Calik MW. Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nat Sci Sleep. 2017;9:127.
   PubMed Web of Science ®Google Scholar
• Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:200–207.
   PubMed Web of Science ®Google Scholar
• Romigi A, Vitrani G, Lo Giudice T, et al. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:2665.
   PubMed Web of Science ®Google Scholar
• Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018;41(12).
   PubMed Web of Science ®Google Scholar
• Carter LP, Henningfield JE, Wang YG, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol,a selective dopamine andnorepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351–1361.
   PubMed Web of Science ®Google Scholar
• Slater G, Steier J. Excessive daytime sleepiness in sleep disorders. J Thorac Dis. 2012;4(6):608.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Tafti M, Landolt HP. Catechol-O-methyltransferase, dopamine, and sleep-wake regulation. Sleep Med Rev. 2015;22:47–53.
   PubMed Web of Science ®Google Scholar
• Burgess CR, Tse G, Gillis L, et al. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep. 2010;33(10):1295–1304.
   PubMed Web of Science ®Google Scholar
• Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367–376.
   PubMed Web of Science ®Google Scholar
• Hasan S, Pradervand S, Ahnaou A, et al. How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropsy chopharmacol. 2009;34(7):1625.
   PubMed Web of Science ®Google Scholar
• Zomorodi K, Kankam M, Lu Y. A phase I, randomized, crossover, open-label study of the pharmacokinetics of solriamfetol (JZP-110) in healthy adult subjects with and without food. Clin Ther. 2019;41(2):196–204.
   PubMed Web of Science ®Google Scholar
• Zomorodi K, Chen D, Lee L, et al. Single-dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019 Mar 13. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102–1108.
   PubMed Web of Science ®Google Scholar
• Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379–1387.
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–370.
   PubMed Web of Science ®Google Scholar
• Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;4:139.
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32–41.
   PubMed Web of Science ®Google Scholar
• Golicki D, Bala MM, Niewada M, et al. Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit. 2010;16(8):RA177–6.
   PubMed Web of Science ®Google Scholar
• Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2019;199(11):1421–1431.
   PubMed Web of Science ®Google Scholar
• Strollo PJ Jr, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: placebo-controlled randomized withdrawal study. Chest. 2019;155(2):364–374.
   PubMed Web of Science ®Google Scholar
• Gasa M, Tamisier R, Launois SH, et al. Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure. J Sleep Res. 2013;22(4):389–397.
   PubMed Web of Science ®Google Scholar